{"doi":"10.1002/mdc3.14018","title":"Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa","abstract":"BACKGROUND: Foslevodopa/foscarbidopa is a subcutaneous infusion of levodopa/carbidopa prodrugs. OBJECTIVES: Assess correlations between sleep and efficacy from interim data of a phase 3 trial of foslevodopa/foscarbidopa (NCT03781167). METHODS: Pearson correlations between sleep (Parkinson's Disease Sleep Scale-2 [PDSS-2]) and quality of life (QoL; Parkinson's Disease Questionnaire-39), motor experiences of daily living (m-EDL; Movement Disorder Society-Unified Parkinson's Disease Scale Part II), and \"Off\"/\"On\" times were calculated for baseline and week 26 improvements. Regression analyses were adjusted for baseline PDSS-2 score. RESULTS: Baseline sleep correlated moderately with QoL (r = 0.44, P < 0.001) and weakly with m-EDL (r = 0.28; P < 0.001). Sleep improvement weakly correlated with improved \"Off\" time (r = 0.37; P < 0.001) and QoL (r = 0.36; P < 0.001). Regression analyses demonstrated significant positive associations for improved sleep, \"Off\" time, QoL, and m-EDL. CONCLUSIONS: Improved sleep with foslevodopa/foscarbidopa was associated with improved QoL and \"Off\" time.","journal":"Movement Disorders Clinical Practice","year":2024,"id":430332,"datarank":0.8079033482862019,"base_score":2.995732273553991,"endowment":2.995732273553991,"self_citation_contribution":0.4493598410330987,"citation_network_contribution":0.3585435072531033,"self_endowment_contribution":0.4493598410330987,"citer_contribution":0.3585435072531033,"corpus_percentile":null,"corpus_rank":null,"citation_count":19,"citer_count":12,"citers_with_citation_signal":10,"citers_with_endowment":10,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9631,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT03781167"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":17410,"name":"Maurizio Facheris","orcid":"0009-0002-4854-6873","position":1,"is_corresponding":false},{"id":1018557,"name":"Bruno Bergmans","orcid":"0000-0002-1463-8262","position":2,"is_corresponding":false},{"id":1018558,"name":"Filip Bergquist","orcid":"0000-0002-3437-0267","position":3,"is_corresponding":false},{"id":465244,"name":"Susan R. Criswell","orcid":"0000-0001-8467-371X","position":4,"is_corresponding":false},{"id":228504,"name":"Jia Jia","orcid":"0000-0001-6395-9487","position":5,"is_corresponding":false},{"id":668823,"name":"Pavnit Kukreja","orcid":null,"position":6,"is_corresponding":false},{"id":1233309,"name":"Yohei Mukai","orcid":"0000-0003-2930-5003","position":7,"is_corresponding":false},{"id":1019251,"name":"Amy M. Spiegel","orcid":null,"position":8,"is_corresponding":false},{"id":546628,"name":"Resmi Gupta","orcid":"0000-0001-6552-4372","position":9,"is_corresponding":false},{"id":668268,"name":"Lars Bergmann","orcid":"0000-0002-8603-8549","position":10,"is_corresponding":false},{"id":473073,"name":"Rajesh Pahwa","orcid":"0000-0003-3176-6466","position":11,"is_corresponding":false},{"id":656916,"name":"К. Ray Chaudhuri","orcid":"0000-0003-2815-0505","position":0,"is_corresponding":true}],"reference_count":28,"raw_metadata":null,"created_at":"2026-07-19T01:59:16.092672Z","pmid":"38465885","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}